Merrimack Opts to Go It Alone in Push Towards Drug Discovery, Bets on its Network Biology | GenomeWeb

Usually, the path from proteomics startup to drug discovery company involves setting up deals to test lead compounds for big pharma. But Merrimack Pharmaceuticals has elected to skip the service stage, and to develop its own lead compounds before knocking on pharma’s door. With a compound currently in clinical trials in the UK and two recent Phase I SBIR grants under its belt, Merrimack is betting that it can make this strategy work.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.